# Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Study · id `cardio:ct-nct07181109` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07181109](<https://clinicaltrials.gov/study/NCT07181109>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07181109

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 11000 participants.

## Technical summary

Registry record NCT07181109. Randomized; quadruple masking; primary purpose treatment. Start 2025-09-06 (actual); primary completion 2030-09-23 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 11000 participants (planned count; ClinicalTrials.gov record NCT07181109, source copy `cardio:ctgov-nct07181109-2026-11-12`, retrieved 2026-11-18)
- Started: 2025-09-06 (actual) (ClinicalTrials.gov record NCT07181109, source copy `cardio:ctgov-nct07181109-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2030-09-23 (anticipated) (ClinicalTrials.gov record NCT07181109, source copy `cardio:ctgov-nct07181109-2026-11-12`, retrieved 2026-11-18)
- Completion: 2030-09-23 (anticipated) (ClinicalTrials.gov record NCT07181109, source copy `cardio:ctgov-nct07181109-2026-11-12`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; France; Germany; Greece; Hungary; India; Italy; Japan; Mexico; Netherlands; New Zealand; Poland; Portugal; Romania; Serbia; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT07181109, source copy `cardio:ctgov-nct07181109-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07181109-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- Acronym: ZENITH
- Condition: High Risk Cardiovascular Disease
- Condition: Hypertension
- Condition: High Cardiovascular Risk
- Intervention (Drug): Zilebesiran
- Intervention (Drug): Placebo
- Lead sponsor: Alnylam Pharmaceuticals
- Lead sponsor class: INDUSTRY
- Collaborator: Hoffmann-La Roche
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Alnylam Pharmaceuticals (`cardio:org-alnylam-pharmaceuticals`)
- Registry lists this organization as a collaborator: Hoffmann-La Roche (`cardio:org-hoffmann-la-roche`)

## Provenance

Content hash: 5b758b4ece046b07850dcf9f11d1f07aa5b2d5b3829567f5e9df2f6e87365358
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
